Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.
Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD, Taylor A, Evans JK, Horgan KJ. Hesketh PJ, et al. Among authors: gralla rj. Support Care Cancer. 2006 Apr;14(4):354-60. doi: 10.1007/s00520-005-0914-4. Epub 2006 Feb 1. Support Care Cancer. 2006. PMID: 16450086 Clinical Trial.
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group. Hesketh PJ, et al. Among authors: gralla rj. J Clin Oncol. 2003 Nov 15;21(22):4112-9. doi: 10.1200/JCO.2003.01.095. Epub 2003 Oct 14. J Clin Oncol. 2003. PMID: 14559886 Clinical Trial.
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, Evans JK, Horgan KJ. Gralla RJ, et al. Cancer. 2005 Aug 15;104(4):864-8. doi: 10.1002/cncr.21222. Cancer. 2005. PMID: 15973669 Free article. Clinical Trial.
Antiemetic guidelines: creating a more practical treatment approach.
Koeller JM, Aapro MS, Gralla RJ, Grunberg SM, Hesketh PJ, Kris MG, Clark-Snow RA. Koeller JM, et al. Among authors: gralla rj. Support Care Cancer. 2002 Oct;10(7):519-22. doi: 10.1007/s00520-001-0335-y. Epub 2002 Feb 21. Support Care Cancer. 2002. PMID: 12324805
Delayed emesis: moderately emetogenic chemotherapy.
Roila F, Warr D, Clark-Snow RA, Tonato M, Gralla RJ, Einhorn LH, Herrstedt J. Roila F, et al. Among authors: gralla rj. Support Care Cancer. 2005 Feb;13(2):104-8. doi: 10.1007/s00520-004-0700-8. Epub 2004 Nov 12. Support Care Cancer. 2005. PMID: 15549426 Review.
265 results